The benefits of end-to-end formulation and fill-finish of biologics

Comprehensive mRNA Solutions

The M.O. Behind Choosing a CDMO: Three Considerations for New Drug Developers

A Year In Review — Curia’s (formerly AMRI) Contributions to Science in 2020

The Shift Toward US Pharmaceutical Manufacturing: Considerations in Attaining the Right Global Mix

COVID-19: Updates from AMRI

Selected AMRI Publications and Patents from 2005–2019

2019: A Year in Review — AMRI’s Contributions to Science